Loading...
To date, antiobesity drugs have produced limited weight loss and substantial adverse effects. Tesofensine, an investigational drug that inhibits presynaptic uptake of noradrenaline, dopamine, and serotonin, produced unintended weight loss in obese patients with Parkinson or Alzheimer disease and did not raise blood pressure or affect mood.
In a manufacturer-supported phase II trial, researchers randomized 203 obese adults to receive daily tesofensine (0.25 mg, 0.5 mg, or 1.0 mg) or placebo for 24 weeks. All participants received instructions on dieting and daily exercise; 161 (79%) completed the trial.
In an intent-to-treat analysis, adjusted mean weight reductions (beyond that in the placebo group) were 4.5 kg, 9.2 kg, and 10.6 kg in the low…